@prefix dct: . @prefix go: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix atcc: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:16384; a Protein: . sub:_2 belv:translocationFrom go:0005622; belv:translocationOf sub:_3; belv:translocationTo go:0009986 . sub:_3 geneProductOf: hgnc:6152; a Protein: . sub:_4 occursIn: atcc:CRL-1593.2.aspx, species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:TRIM28) -> surf(p(HGNC:ITGAX))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_6; pav:version "1.4" . sub:_5 prov:value "Conversely, because the TIF1? antisense-ribozymes had no effect on GAPDH mRNA levels (Fig. 1D, bottom panel), they appear to be specific for the TIF1? mRNAs. These data show that the TIF1? antisense-ribozymes specifically ablate expression of endogenous TIF1? mRNA. As seen in Figure 2B, CD11b, CD11c, and CD14 levels increased in response to PMA-treatment of U937 clones expressing the ?-gal antisense-ribozyme. However, expression did not increase in the TIF1? antisense-ribozyme stable U937 cell lines.."; prov:wasQuotedFrom pubmed:11711437 . sub:_6 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:11711437; prov:wasDerivedFrom beldoc:, sub:_5 . } sub:pubinfo { this: dct:created "2014-07-03T14:29:59.148+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }